Market
55 articles in the Market category
HumeCare Oral GLP-1 Review 2026: A Closer Look at the Option
A 2026 review of HumeCare's oral GLP-1 product examines whether it could serve as a convenient alternative to injectable options. The article highlights the growing interest in oral formulations and what HumeCare offers. It provides an overview of the product's potential role in the market.
6 min readPolyPeptide Group Stock Holds Below CHF 44 Despite Margin Gains
PolyPeptide Group (SWX:PPGN) shares continue to trade under the CHF 44 offer price despite recent margin momentum, according to a market analysis. The article examines the disconnect between the company's improving margins and its stock price performance. Investors are watching whether the gap between fundamentals and valuation will close.
5 min read
PolyPeptide Reports Strong H1 2026 Growth and Raises Full-Year Guidance
PolyPeptide Group delivered robust financial results for the first half of fiscal 2026, prompting management to lift its full-year outlook. The earnings call transcript, published on Investing.com, details the company's improved revenue and profitability metrics. Executives cited strong demand across its peptide CDMO services as a key driver.
5 min read
Eli Lilly targets black market for experimental weight-loss drug
Eli Lilly is taking action against the illicit market for its experimental weight-loss drug. The company is reportedly addressing unauthorized sales of the medication. This move comes as demand for weight-loss treatments continues to rise.
5 min readGLP-1 Users Cut Grocery Spending, Food Dive Reports
A Food Dive report indicates that people taking GLP-1 medications are reducing their grocery purchases. The article, published on August 12, 2026, highlights a notable decline in food spending among this group. This trend reflects changing consumption patterns linked to the use of these drugs.
5 min read
Yale Study Could Reshape Understanding of GLP-1 Drugs
A new study from YaleNews, published August 10, 2026, may change how researchers and clinicians think about GLP-1 receptor agonists. The findings challenge existing assumptions about these widely used medications, potentially influencing future therapeutic approaches and research directions.
5 min read
GLP-1 Stock Showdown: Eli Lilly vs. Viking Therapeutics
Investors weighing GLP-1 exposure often compare Eli Lilly and Viking Therapeutics. This analysis reviews both companies' positions in the weight-loss drug market, highlighting key differences in pipeline maturity, clinical data, and market valuation. The article presents the facts to help readers decide which stock might be the better buy.
5 min read
CVS Health Expands GLP-1 Access With $29 Visits, Lilly Deal
CVS Health is broadening patient access to GLP-1 medications through $29 virtual visits and a new partnership with Eli Lilly. The initiative aims to simplify prescribing and lower cost barriers for weight-management drugs. Details of the collaboration and visit pricing were announced in a recent Pharmacy Times report.
5 min read
Tirzepatide Tied to Reduced Heart Attack Risk in High-Risk Patients
A recent report highlights that the GLP-1 drug tirzepatide is associated with a lower risk of heart attacks in patients considered high-risk. The finding adds to growing evidence of cardiovascular benefits for this class of medications. Details from the WDBJ7 report are summarized here.
5 min readAmazon Pharmacy Launches $50 Monthly GLP-1 Program via Medicare Bridge
Amazon Pharmacy has introduced a new program offering GLP-1 medications for $50 per month through its Medicare Bridge initiative. The service aims to make these popular weight-loss and diabetes drugs more affordable for eligible patients. This move could significantly impact the competitive landscape of online pharmacy and specialty drug pricing.
5 min readNovo Nordisk's GLP-1 lead slips: Can Europe compete globally?
Novo Nordisk, maker of Ozempic, has lost its dominant position in the GLP-1 weight-loss drug market. The company's struggles raise questions about Europe's ability to compete in the high-stakes global economy.
5 min readLilly Q2 Revenue Hits $23B, Beats Forecasts; Oral GLP-1 Foundayo Trails Novo
Eli Lilly reported second-quarter revenue of $23 billion, surpassing analyst expectations. However, the company's oral GLP-1 drug Foundayo is lagging behind Novo Nordisk's competing oral GLP-1 treatment. The results highlight the competitive dynamics in the weight-loss and diabetes drug market.
5 min read
Why 90% of GLP-1 Users Still Buy Ice Cream: Market Insights
A new report from FoodNavigator.com asks why 90% of people taking GLP-1 drugs continue to purchase ice cream despite the appetite-suppressing effects of these medications. The article explores the apparent contradiction between the popularity of these drugs and unchanged consumer behavior in the frozen dessert aisle.
5 min read
Novo Nordisk fights back in obesity drug race against Eli Lilly
Novo Nordisk is reasserting itself in the competitive obesity treatment market, challenging Eli Lilly's recent dominance. The renewed rivalry highlights the high stakes in the rapidly expanding weight-loss drug sector. Both companies are vying for a larger share of this lucrative market.
5 min read
South Korea to flag Wegovy, Mounjaro for abuse as sales surge
South Korea is set to flag Novo Nordisk's Wegovy and Eli Lilly's Mounjaro for potential abuse as sales of the GLP-1 drugs surge in the country. The move comes amid growing concerns over misuse and diversion of these popular weight-loss and diabetes medications.
5 min read
Doctor Weighs In: Oral Wegovy Pill Versus Injection
A doctor offers an honest comparison between the new oral Wegovy pill and the traditional injection. The article examines how the two forms differ in delivery, effectiveness, and patient experience, based on the physician's perspective.
5 min read
Novo Nordisk Shares Drop as Heart Drug Trial Fails, Pipeline Hit
Novo Nordisk's shares plunged after its experimental heart medicine failed a late-stage trial, delivering another setback to the company's pipeline. The news adds to recent challenges for the Danish drugmaker, which has been working to diversify beyond its diabetes and obesity treatments.
5 min read
Meredith Marks Reveals Beauty Routine: Copper Peptide Shots and Caviar Yogurt
In an exclusive interview, Meredith Marks shares her unconventional beauty regimen, which includes copper peptide injections and caviar yogurt. The reality star details her skincare philosophy and the treatments she credits for her youthful appearance.
5 min read
Novo Nordisk Earnings Preview: What Investors Should Watch
Morningstar has published a preview of Novo Nordisk's upcoming earnings report, highlighting key factors investors should monitor. The article, dated July 31, 2026, focuses on the company's performance in the competitive GLP-1 drug market. Analysts are watching for updates on sales trends and pipeline developments.
5 min readSamsung Biologics PolyPeptide Acquisition Surprised Industry Analysts
Samsung Biologics' acquisition of PolyPeptide Group surprised industry observers, according to a PharmTech.com report. The deal marked a significant expansion for the South Korean contract development and manufacturing organization into the peptide space. Analysts had not anticipated this specific move by Samsung Biologics.
5 min read
European Doctors See High Appetite for Wegovy Pill if Novo Nordisk Secures Access
A survey of European physicians indicates significant demand for Novo Nordisk's oral Wegovy formulation, provided the company can navigate access and reimbursement hurdles. The findings suggest strong prescribing intent once the pill becomes available, highlighting a major market opportunity for the GLP-1 drug in Europe.
5 min read
Global Demand for Weight-Loss Drugs Clashes with Advertising Restrictions
A CNN report highlights the paradox of soaring global demand for weight-loss medications from companies like Novo Nordisk and Lilly, while strict advertising regulations prevent Big Pharma from marketing these drugs in many countries. The article explores the tension between desperate patients and regulatory barriers that limit direct-to-consumer promotion.
5 min read
Pharma Giants Clash Over Anti-Obesity Drug Advertisements
Major pharmaceutical companies are reportedly clashing over advertisements for anti-obesity drugs. The conflict involves competing claims and marketing strategies in the rapidly growing weight-loss medication market. The dispute highlights the intense competition among drugmakers targeting obesity treatment.
5 min readSamsung Biologics bids 1.46 billion CHF in cash to acquire PolyPeptide
Samsung Biologics has launched a cash offer valued at 1.46 billion Swiss francs to acquire PolyPeptide, a contract development and manufacturing organization specializing in peptide-based therapeutics. The bid represents a significant move by the South Korean CDMO to expand its capabilities in the peptide drug manufacturing sector.
4 min read
Peptide Coupling Reagents Market Analysis and Forecast to 2036
Future Market Insights has published a global industry analysis and opportunity assessment for the peptide coupling reagents market, projecting trends through 2036. The report provides a comprehensive evaluation of market dynamics, key players, and regional opportunities. It covers the entire forecast period from the base year to 2036.
3 min read
GLP-1 Drugs Linked to Reduced Crime-Related Behavior
A report from Inside Precision Medicine indicates that GLP-1 receptor agonists, commonly used for diabetes and weight loss, may be associated with a reduction in crime-linked behaviors. The findings suggest potential broader societal impacts of these medications beyond metabolic health.
2 min readZepbound: Setting Weight Loss Goals May Boost Success, Study Suggests
A new article from Healthline reports that setting specific weight loss goals may be critical for success with the GLP-1 drug Zepbound. The piece highlights how structured goal-setting can improve outcomes for patients using the medication.
2 min read
Ozempic and Wegovy linked to drop in violent behavior, study finds
A new study has found that the popular GLP-1 drugs Ozempic and Wegovy are linked to a decrease in violent behavior among users. The research, reported by NewsNation, adds to the growing body of evidence suggesting these medications may have broader effects beyond weight loss and blood sugar control.
2 min read
EU Calmodulin-Binding Peptide Resins Market Analysis and Forecast 2026
IndexBox has published a new report analyzing the European Union market for calmodulin-binding peptide resins. The analysis covers market size, trends, and forecasts for the region. The report provides detailed insights into production, consumption, trade, and pricing dynamics across EU member states.
2 min read
GLP-1 Drugs Linked to Lower Death and Clot Risk in Autoimmune Patients
A new study reported by U.S. News & World Report on June 17, 2026, found that autoimmune patients taking GLP-1 drugs had a lower risk of death and blood clots. The findings suggest additional benefits for this patient population beyond weight management and blood sugar control.
2 min readNovo Nordisk Expands Wegovy Pill Reach and Global Obesity Model
Novo Nordisk is expanding the reach of the Wegovy pill. The company is also building a global obesity care model. These actions were noted in reports dated 2026-06-03.
1 min readOxurion Launches Service for GLP-1 and Peptide Therapies
Oxurion has launched a dedicated service offering for GLP-1 and peptide therapies. The news was reported by Idéal Investisseur. The announcement occurred on June 3, 2026.
2 min read
Novo Nordisk Launches Wegovy Pill in UAE as First Market
Novo Nordisk is launching its weight loss pill Wegovy in the United Arab Emirates. The move marks the Danish drugmaker's first launch of the pill outside the United States. The company plans to expand to additional select countries in the coming months based on specific criteria.
3 min readBachem Holding AG Stock in Focus After Guidance Update
Bachem Holding AG stock, with ISIN CH0012530207, has drawn investor attention as a peptide specialist. The focus follows a recent guidance update from the company. This matter appears in ad hoc news coverage.
1 min readGLP-1 Weight Loss Drugs Create Wedding Dress Challenges for Brides
GLP-1 weight loss drugs are creating wedding dress challenges for brides. These medications are causing issues with bridal gowns during wedding preparations. Brides using GLP-1 drugs face specific difficulties with their dresses.
2 min readWeight-Loss Jabs Halve Sick Days and Free Millions of GP Slots
Weight-loss jabs halve sick days taken by users. These injections also free up millions of GP slots. The effects point to changes in work attendance and primary care demands.
1 min readEli Lilly Commits $50M Over Six Years to UNICEF USA
Eli Lilly has pledged $50 million over six years to UNICEF USA. The funds support work on preventing, detecting, and managing noncommunicable diseases. This commitment aids global pediatric health initiatives through UNICEF.
1 min read
Eli Lilly Stock Targets $1,164.85 After Q1 Surge
Eli Lilly reported strong Q1 2026 results with revenue of $19.799 billion, surpassing estimates by 11.25%. The company raised its full-year guidance, and shares have risen 9.27% in the past month. A price target of $1,164.85 suggests 14.68% upside from $1,015.75.
3 min readMetabolic Surgery Rates Drop as GLP-1 Uptake Increases
Uptake of GLP-1 continues to climb in patient care. At the same time, rates for metabolic surgery show a clear decline. These parallel developments mark a notable change in approaches to metabolic conditions.
1 min readGLP-1 Users Taking Bite Out of Restaurant Business
GLP-1 users are taking a bite out of the restaurant business. This impact affects restaurant operations and revenues directly. The trend shows users reducing their contribution to the sector.
2 min readNovo Nordisk, Eli Lilly Highlight GLP-1 Data on Weight Loss Speed and Maintenance
Novo Nordisk and Eli Lilly are presenting data on their incretin drugs for obesity treatment. Novo Nordisk emphasizes early response for faster weight loss. Eli Lilly focuses on weight loss maintenance with both new and established options. This occurs as competition in the GLP-1 field grows more intense.
2 min read
Lilly Trials Indicate Maintenance Options for GLP-1 Weight Loss
Eli Lilly has released data from two trials showing that patients using injectable GLP-1 drugs like Zepbound or Wegovy can maintain most weight loss with continued treatment, lower doses, or the Foundayo pill. In both studies, these approaches outperformed placebo over a year. The results appeared in The Lancet and Nature Medicine alongside an obesity conference in Europe.
3 min readBachem Holding AG, Peptide Leader, Eyes US Biotech Growth
Bachem Holding AG, a leader in peptides, focuses on growth in the US biotech sector. The company's stock carries the identifier CH0012530207. This development comes via AD HOC NEWS.
2 min readEli Lilly Slimming Pill Delivers Sustained Weight Loss in Study
A new study indicates that Eli Lilly's slimming pill produces sustained weight loss. The findings highlight the pill's effectiveness over time. This development comes from recent research on the company's weight management treatment.
2 min read
Global Peptide Therapeutics Market to Reach USD 444.8 Billion
The global peptide therapeutics market will reach USD 444.8 billion. This projection sets the expected value for the worldwide sector. The figure USD 444.8 billion applies directly to peptide therapeutics on a global scale.
1 min readDaily Pill Prevents Weight Regain After Obesity Jabs
A daily pill assists in keeping weight off after patients stop obesity jabs. Obesity jabs serve as injection treatments for weight management in obesity cases. The pill supports ongoing weight control during the period following discontinuation of the jabs.
2 min readFrance Penalizes Novo Nordisk and Eli Lilly for Anti-Obesity Drug Ads
French authorities have imposed fines on Novo Nordisk and Eli Lilly due to advertisements for their anti-obesity drugs.
2 min readDeloitte Warns GLP-1 Boom Risks 'Bubble Effect' in Big Pharma
Deloitte cautions that the GLP-1 surge may trigger a 'bubble effect,' reducing rivalry among large pharmaceutical firms. This comes amid strong market growth from players like Novo Nordisk and Lilly. The analysis raises the issue: 'The Question Is...
2 min readNovo Nordisk GLP-1 Pill Lead Prompts Rethink of Eli Lilly Dominance
Novo Nordisk holds an early advantage in GLP-1 pills, according to CNBC. This development leads investors to reassess Eli Lilly's strong position in the market. The situation highlights competition in oral GLP-1 formulations.
2 min readEli Lilly Secures 60% GLP-1 Market Share as Mounjaro Revenue Rises 125%
Eli Lilly has taken 60% of the GLP-1 market, according to 24/7 Wall St. The company's Mounjaro product saw revenue grow by 125%.
1 min readIndexBox EU PRRT Market Analysis: Forecast, Size, Trends
IndexBox has published a report on the European Union market for Peptide Receptor Radionuclide Therapy, or PRRT. The document covers market analysis, forecasts, size, trends, and insights.
2 min readBachem Assigns CEO to Commercial Chief After Exec Exit
Bachem has placed its CEO in the commercial chief role following an executive's departure. Stock Titan reported the leadership change for the peptide CDMO. The announcement occurred on May 5, 2026.
2 min readFrailty Rather Than Age Drives Risks of SGLT2, GLP-1 Meds
Medscape reports that frailty, rather than age, determines risks with SGLT2 and GLP-1 medications. This finding shifts attention to patient frailty levels.
1 min readPharma Roundup: Hormuz Instability Hits Generics, Daraxonrasib Boosts Pancreatic Survival
Geopolitical tensions in the Strait of Hormuz disrupt generic drug supplies through shipping slowdowns. Daraxonrasib extends survival in metastatic pancreatic cancer over standard chemotherapy. Sparsentan (Filspari) gains approval for focal segmental glomerulosclerosis, amid other advances in vaccines, stroke care, and AI health tools.
3 min readHormuz Tensions Threaten Generic Drugs; Daraxonrasib Aids Pancreas Cancer
Geopolitical issues in the Strait of Hormuz slow shipments of pharmaceutical ingredients and generic drugs worldwide. Daraxonrasib extends survival in metastatic pancreatic cancer over chemotherapy. Sparsentan (Filspari) gains approval for focal segmental glomerulosclerosis, amid other pharma advances.
4 min readOther categories